Blue Biofuels Inc (BIOF) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 3, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 10, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the BIOF SEC filings page.
This page shows Blue Biofuels Inc (BIOF) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Blue Biofuels operates as a development-stage business financed externally while reported revenue remains absent.
Cash generation is improving but not self-funding: operating cash outflow narrowed from-$2.5M in FY2021 to-$845K in FY2025, yet FY2025 financing inflows of$999K still exceeded that operating outflow before investing needs. The combination indicates lower annual cash consumption, not a shift to internally financed operations.
Research investment remains the central operating commitment: FY2025 R&D was
Balance-sheet liquidity has tightened materially: current assets were only
Financial Health Signals
Blue Biofuels Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Blue Biofuels Inc passes 1 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
Blue Biofuels Inc reported a net loss of $2.9M while operations used $845K of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Blue Biofuels Inc's EBITDA was -$702K in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 19.5% from the same quarter a year earlier. Against the prior quarter it is down 11.8%.
Blue Biofuels Inc reported -$751K in net income in Q2 2026. This represents an increase of 18.5% from the same quarter a year earlier. Against the prior quarter it is down 13.1%.
Blue Biofuels Inc earned $0.00 per diluted share (EPS) in Q2 2026. This represents an increase of 33.3% from the same quarter a year earlier. It is unchanged from the prior quarter.
Not reported for Q2 2026.
Cash & Balance Sheet
Blue Biofuels Inc held $22K in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
None of these metrics is reported for Q2 2026.
Capital Allocation
Blue Biofuels Inc invested $431K in research and development in Q2 2026. This represents a decrease of 8.5% from the same quarter a year earlier. Against the prior quarter it is up 12.0%.
Not reported for Q2 2026.
Not reported for Q2 2026.
BIOF Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $431K-8.5% | $385K+9.8% | N/A | $486K+18.2% | $471K+61.8% | $351K-42.3% | N/A | $411K+39.9% |
| SG&A Expenses | $397K-7.8% | $275K-18.8% | N/A | $351K+47.9% | $431K+72.6% | $338K+14.2% | N/A | $237K+8.1% |
| Operating Income | -$731K+19.0% | -$659K+4.3% | N/A | -$836K-29.1% | -$903K-66.8% | -$689K+23.8% | N/A | -$648K-26.3% |
| EBITDA | -$702K+19.5% | -$628K+4.7% | N/A | -$805K-30.2% | -$872K-70.6% | -$659K+24.6% | N/A | -$618K-28.0% |
| Interest Expense | $20K+8.5% | $4K | N/A | N/A | $18K | N/A | N/A | N/A |
| Net Income | -$751K+18.5% | -$664K-172.2% | N/A | -$423K-122.6% | -$921K-67.8% | -$244K+74.2% | N/A | $1.9M+662.1% |
| EPS (Basic) | $0.00+33.3% | $0.00-100.0% | $0.00+33.3% | $0.00-116.7% | $0.00-50.0% | $0.00+66.7% | -$0.01-200.0% | $0.01+700.0% |
| EPS (Diluted) | $0.00+33.3% | $0.00-100.0% | $0.00+33.3% | $0.00-116.7% | $0.00-50.0% | $0.00+66.7% | -$0.01-200.0% | $0.01+700.0% |
| Diluted Shares (Avg) | 321M+3.6% | 319M+3.5% | N/A | 312M-1.5% | 310M+2.4% | 308M+1.9% | N/A | 317M+5.7% |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Income Tax.
BIOF Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.3M-8.8% | $1.3M-11.7% | $1.4M+1.3% | $1.5M-0.2% | $1.4M+10.9% | $1.5M+51.7% | $1.4M+34.9% | $1.5M+19.2% |
| Current Assets | $34K+75.0% | $20K-49.6% | $77K-5.6% | $107K-50.7% | $19K-95.6% | $40K-29.8% | $81K+5.9% | $216K-14.7% |
| Cash & Equivalents | $22K+174.6% | $9K+14.3% | $65K+33.6% | $95K-36.3% | $8K-98.0% | $8K-68.8% | $49K+19.0% | $149K+76.4% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $5.4M+16.4% | $5.2M+18.3% | $5.1M+20.7% | $4.5M+13.6% | $4.6M-23.7% | $4.4M-14.7% | $4.2M-7.7% | $4.0M-7.9% |
| Current Liabilities | $3.4M+37.8% | $3.1M+33.9% | $3.0M+34.9% | $2.4M+22.2% | $2.5M+23.1% | $2.3M+12.7% | $2.2M+47.2% | $2.0M+48.4% |
| Non-Current Liabilities | $2.0M-7.6% | $2.1M+1.1% | $2.1M+5.2% | $2.2M+5.3% | $2.2M-46.7% | $2.1M-32.7% | $2.0M-34.5% | $2.0M-32.4% |
| Total Equity | -$4.1M-28.0% | -$3.9M-33.4% | -$3.7M-30.2% | -$3.1M-21.7% | -$3.2M+33.3% | -$3.0M+30.0% | -$2.8M+20.1% | -$2.5M+18.8% |
| Retained Earnings | -$61.5M-5.3% | -$60.8M-5.7% | -$60.1M-5.0% | -$58.8M-6.1% | -$58.4M-1.9% | -$57.5M-1.3% | -$57.3M-2.5% | -$55.5M-0.2% |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
BIOF Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$269K+13.9% | -$419K-3219.7% | -$392K-85.0% | -$154K+37.9% | -$312K-8.6% | $13K+105.2% | -$212K-100.1% | -$248K+21.0% |
| Depreciation & Amortization | $29K-4.1% | $31K+4.8% | $18K-37.9% | $31K+5.9% | $30K+1.8% | $30K+0.4% | $30K-1.0% | $30K-0.6% |
| Stock-Based Compensation | N/A | $77K-12.8% | N/A | $259K+91.5% | $351K+1080.2% | $88K-68.4% | N/A | $135K |
| Capital Expenditures | N/A | N/A | -$1 | -$67K | $32K | $105K | N/A | N/A |
| Free Cash Flow | N/A | N/A | -$392K | -$221K | -$344K | -$91K | N/A | N/A |
| Investing Cash Flow | -$48K-23.6% | -$10K+93.5% | -$10K+88.1% | $66K+735.6% | -$39K-3966.8% | -$155K-642.5% | -$86K-572.5% | -$10K+20.7% |
| Financing Cash Flow | $330K-6.0% | $372K+272.0% | $373K+89.1% | $175K | $351K-47.6% | $100K-61.5% | $197K+162.7% | $0-100.0% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
BIOF Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Debt-to-Equity, Asset Turnover, FCF Margin.
Note: Shareholder equity is negative (-$3.7M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.03), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Blue Biofuels Inc BIOF | FY2025 | N/A | -$2.9M | N/A | $31.2M | — |
| Kraig Biocraft Laboratories In KBLB | FY2025 | N/A | -$3.6M | N/A | $91.5M | — |
| Greystone Logist GLGI | FY2026 | $27.5M | -$8.2M | -29.9% | $7.1M | — |
Where Blue Biofuels Inc Ranks
Frequently Asked Questions
Is Blue Biofuels Inc profitable?
No, Blue Biofuels Inc (BIOF) reported a net income of -$2.9M in fiscal year 2025.
What is Blue Biofuels Inc's EBITDA?
Blue Biofuels Inc (BIOF) had EBITDA of -$3.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Blue Biofuels Inc's free cash flow?
Blue Biofuels Inc (BIOF) recorded an outflow of $914K in free cash flow during fiscal year 2025. This represents a 15.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Blue Biofuels Inc's operating cash flow?
Blue Biofuels Inc (BIOF) recorded an outflow of $845K in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Blue Biofuels Inc's total assets?
Blue Biofuels Inc (BIOF) had $1.4M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Blue Biofuels Inc's capital expenditures?
Blue Biofuels Inc (BIOF) invested $69K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Blue Biofuels Inc spend on research and development?
Blue Biofuels Inc (BIOF) invested $2.3M in research and development during fiscal year 2025.
What is Blue Biofuels Inc's current ratio?
Blue Biofuels Inc (BIOF) had a current ratio of 0.03 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Blue Biofuels Inc's return on assets (ROA)?
Blue Biofuels Inc (BIOF) had a return on assets of -204.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Blue Biofuels Inc's P/E ratio?
Blue Biofuels Inc (BIOF) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $31.2M as of Sep 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Blue Biofuels Inc's price-to-sales ratio?
Blue Biofuels Inc (BIOF) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $31.2M as of Sep 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Blue Biofuels Inc's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Blue Biofuels Inc (BIOF) held $65K in cash, cash equivalents and investments, and reported an operating cash outflow of $845K over that year. Dividing the one by the other, the reported balance equals about 1 month of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Why is Blue Biofuels Inc's debt-to-equity ratio negative or not reported?
Blue Biofuels Inc (BIOF) has negative shareholder equity of -$3.7M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Blue Biofuels Inc's Piotroski F-Score?
Blue Biofuels Inc (BIOF) has a Piotroski F-Score of 1 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Blue Biofuels Inc's earnings high quality?
Blue Biofuels Inc (BIOF) reported a net loss of $2.9M while operations used $845K of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.